Difference between revisions of "Umbralisib (Ukoniq)"
Jump to navigation
Jump to search
m |
|||
| Line 17: | Line 17: | ||
*'''Brand name:''' Ukoniq | *'''Brand name:''' Ukoniq | ||
| + | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Revision as of 02:54, 12 March 2021
Mechanism of action
Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor
Diseases for which it is used
Patient Drug Information
History of changes in FDA indication
- 2/5/2021: Approved for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
- 2/5/2021: Approved for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Also known as
- Code name: TGR-1202
- Brand name: Ukoniq